Lrvine, CA-ISTA Pharmaceuticals Inc. said its bromfenac sodium ophthalmic solution (Xibrom) once-daily formulation produced highly statistically significant results in its phase III clinical trials.
ChatGPT may have a future use in glaucoma
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics
Therapeutic in development to take on diabetic macular edema
Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention
Ocugen completes dosing in subjects with GA secondary to dAMD in Phase 1/2 ArMaDa clinical trial of OCU410
Stress resilience–enhancing drugs: New class of small molecules holds promise